A personalized neoantigen peptide vaccine combined with PD-1 immunotherapy achieved 80% durable tumor regression in liver cancer mouse models by dramatically increasing cancer-killing tissue-resident memory T cells.
80% durable tumor regressionThe combination of a personalized seven-peptide neoantigen vaccine with PD-1 blockade achieved durable tumor regression in 80% of orthotopic liver cancer models — a remarkable response rate for an aggressive cancer that responds poorly to single-agent immunotherapy.
What the researchers found
The neoantigen peptide vaccine (NeoVAC) combined with anti-PD-1 immunotherapy demonstrated:
- 80% durable tumor regression in orthotopic (liver-implanted) HCC mouse models
- Long-term immune memory against the tumor (indicating durable protection against recurrence)
- Dramatically increased CD8+ tissue-resident memory T cells (TRMs) in the tumor microenvironment
- CD8+ TRM infiltration positively correlated with treatment efficacy
- Strong tumor-killing capacity of CD8+ TRMs confirmed both in vitro and in vivo
- Validated in autologous patient-derived HCC cells (human cancer cells killed by TRMs)
The vaccine consisted of seven immunogenic neoantigen peptides with clinical-grade Poly(I:C) adjuvant. Single-cell RNA sequencing revealed the immune mechanisms underlying the synergistic effect.
Why it matters
Hepatocellular carcinoma is the third leading cause of cancer death worldwide, and most patients are diagnosed too late for surgery. Current immunotherapy (PD-1 blockade alone) has limited response rates in liver cancer. This study shows that combining a personalized peptide vaccine with immunotherapy dramatically improves outcomes by recruiting specialized immune cells that remain in the liver long-term. The 80% regression rate and evidence of immune memory are exceptional for an aggressive cancer.
How the study worked
Neoantigen peptides were identified through tumor mutation screening of the murine Hepa1-6 HCC cell line. Seven high-immunogenicity peptides were selected and combined with clinical-grade Poly(I:C) adjuvant to create NeoVAC. Efficacy was tested in an orthotopic (liver-implanted) HCC mouse model, alone and combined with anti-PD-1 antibody. The tumor immune microenvironment was analyzed by single-cell RNA sequencing, tetramer flow cytometry, and immunofluorescence. Tumor-killing capacity of CD8+ TRMs was verified in both mouse and human patient-derived cancer cells.
What this study cannot tell us
All efficacy data are from mouse models, which may not predict human responses. The orthotopic model uses a single mouse cell line (Hepa1-6), limiting diversity. Patient-derived cell validation was done in vitro, not in patients. The seven neoantigen peptides are specific to the mouse tumor line — human patients would require individualized peptide selection. Manufacturing personalized vaccines for each patient is logistically complex and expensive. Long-term durability of the immune response was not assessed beyond the study timeframe.
How to read the evidence
This is a preclinical study using mouse tumor models with additional validation in human patient-derived cells. While the results are striking (80% regression), they come from an animal model and must be validated in human clinical trials before conclusions about therapeutic efficacy can be drawn. Published in a high-impact immunotherapy journal.
When this study was published
Published in 2022, this study is relatively recent and aligns with the rapidly accelerating field of personalized cancer vaccines, which has seen major clinical developments in melanoma and other cancers.
The bigger picture
Personalized cancer vaccines are one of the most promising frontiers in oncology, with mRNA-based neoantigen vaccines (like Moderna's partnership with Merck for melanoma) gaining attention. This study demonstrates that peptide-based vaccines can be equally powerful when combined with checkpoint inhibitors. The identification of CD8+ tissue-resident memory T cells as the key effector population provides a measurable biomarker for predicting treatment success and could guide the design of future combination immunotherapy trials.
Questions still open
- Can this combination approach achieve similar response rates in human clinical trials for hepatocellular carcinoma?
- How long does the immune memory from the peptide vaccine last, and does it protect against cancer recurrence?
- Could CD8+ tissue-resident memory T cell levels serve as a biomarker to predict which liver cancer patients will respond to personalized vaccine therapy?
Common questions
What is a personalized neoantigen peptide vaccine?
Why is combining the vaccine with PD-1 blockade important?
Read the original research
Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.
Journal for immunotherapy of cancer, 10(9)
Citation
Chen, Hengkai; Li, Zhenli; Qiu, Liman; Dong, Xiuqing; Chen, Geng; Shi, Yingjun; Cai, Linsheng; Liu, Wenhan; Ye, Honghao; Zhou, Yang; Ouyang, Jiahe; Cai, Zhixiong; Liu, Xiaolong. (2022). Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.. Journal for immunotherapy of cancer, 10(9). https://doi.org/10.1136/jitc-2021-004389